HEPALINK - Key Persons

Job Titles:

• Secretary

Mr. Fengqi Qian is the Secretary to the Board, Joint Company Secretary and Director of the Board Secretary's Office at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink") where he is responsible for disclosures, shareholder meetings, and daily operations of the board. He serves as a bridge between the company and its investors, building investors' understanding of the company's state of business and helping investors to recognize the company's true value.

Job Titles:

• Chairman
• President

Job Titles:

• Vanke Property Management As Chief Information Technology Officer
• Vice President of Processes, IT and Data at Shenzhen Hepalink Pharmaceutical Group Co

Mr. Mingjie Wu is the Vice President of Processes, IT and Data at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink") where he leads the company's global digital operations, building and optimization of the company's global business process management system, process design and IT strategies, and the management of the company's IT and cyber security infrastructure. In 2015, Mr. Wu joined Vanke Property Management as Chief Information Technology Officer. In that position, he was responsible for the design and building of the company's digital services platform, an intelligent community platform, an internet of things (IOT) platform, and the design, development, and operation of the Live Here app that was used by tens millions of users. These projects were widely regarded as a model digitalization project within the industry.

Job Titles:

• Senior Vice President of Global Industrial Affairs / Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• Senior Vice President of Global Industrial Affairs at Shenzhen Hepalink Pharmaceutical Group Co
• SVP of Global Industrial Affairs

Mr. Ping Zhang is the Senior Vice President of Global Industrial Affairs at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink") where he leads global manufacturing, quality management and regulatory affairs. Mr. Zhang is also the Chief Executive Officer of Hepalink's wholly-owned subsidiary, Cytovance Biologics, Inc., where he is directly in charge of the company's CDMO business.

Job Titles:

• Master of Business and Computer Science / Senior Vice President of Global Supply Chain
• Senior Vice President of Global Supply Chain at Shenzhen Hepalink Pharmaceutical Group Co
• SVP of Global Supply Chain

Mr. Xi Gao is Senior Vice President of Global Supply Chain at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink") where he is in charge of the group's procurement center and improving the operational and manufacturing efficiency in the API business of Hepalink's subsidiaries in the U.S. Mr. Gao has over 20 years of experience in supply chain management. Before joining Hepalink, Mr. Gao was Director for APAC Procurement at Colgate (China) Co., Ltd. During this period, Mr. Gao provided direct leadership to procurement and supply teams in China, Thailand, Vietnam and Myanmar, managing strategic procurement, cost optimization, supply chain security, quality assurance, as well as supply chain system/data/processes optimizations for the entire APAC region. In addition, he also led the negotiations in the global procurement of key raw materials. Prior to that, Mr. Gao worked at Shell (China) since 2010, as Senior Manager for planning, Greater China, and APAC Director for procurement for downstream businesses. During this time, Mr. Gao led both direct and indirect procurement teams in Asian countries including China, Thailand, Singapore, Philippines in initiatives in supply chain security, procurement efficiency, and cost optimization. While at Shell, Mr. Gao led the development a digital contract management and supplier performance tracking system, for which he was named a recipient of the 2014 Best Global Project Award. During 2008 and 2010, Mr. Gao worked at Johnson and Johnson (APAC) Co., Ltd., responsible for packaging material procurement for consumer products and successfully delivered numerous supply chain optimization programs in the region. Mr. Gao has a Master of Business and Computer Science degree from Victoria University, Australia.

Job Titles:

• Executive Director
• General Manager
• Vice President
• Co - Founder, Executive Director, General Manager and Vice President

Mr. Yu Shan is an Executive Director, General Manager and Vice President of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink"). He is also a Co-Founder of the company and a member of the group management council in charge of business development, external affairs, and safety management. Since co-founding Hepalink in 1998, Mr. Shan provided vital leadership that has brought the company uninterrupted profitability and the successful listing in both mainland China and Hong Kong. Meanwhile, the company's lead product, enoxaparin sodium injection, as the first generic enoxaparin in China and the EU, is now sold to over 40 countries and regions around the world, achieving widespread recognition in markets with high entry standards. Under its co-founders' effective leadership, Hepalink has built a vibrant ecosystem of synergistic businesses in heparin industrial chain, CDMO services, and innovative drugs. Furthermore, Mr. Shan has made integral contributions to the building and development of Hepalink's manufacturing sites, including the Duopule site, and the Pingshan Industrial Park. Last but not least, Mr. Shan also developed Hepalink's strategic planning capabilities leading the corporate strategy development for the company. Before founding Hepalink, Mr. Shan was General Manager at Shenzhen Yuanzheng Pharmaceutical Co., Ltd. Prior to that, he worked at the Chinese Institute of Atomic Energy. Mr. Shan has a Bachelor of Science degree from Peking University.

Job Titles:

• General Operations Manager of Industrial Real Estate Business / Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• General Operations Manager of Industrial Real Estate Business at Shenzhen Hepalink Pharmaceutical Group Co

Ms. Jie Zhang is the General Operations Manager of Industrial Real Estate Business at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink") where she leads the company's industrial real estate business, overseeing the development and asset management of the company's industrial parks in China. Ms. Zhang has over 20 years of experience in the end-to-end development, operations, and management of residential, commercial and industrial real estate properties. During 2002 and 2020, Ms. Zhang was General Manager of Group Development Center, General Manager of Sales Marketing, at a developer controlled by the Fantasia Holdings Group; Director and Vice President at Home E&E Commercial Services Group, another subsidiary of Fantasia. Under Ms. Zhang's leadership, her team has achieved outstanding market success with the company's three flagship product lines. Through vertical integrations, effective targeted marketing and innovative business models, she successfully completed an array of flagship projects such as the Intelligent Manufacturing Accelerator Park of Shenzhen Nanshan Science and Technology City. Ms. Zhang holds several positions outside her professional responsibilities, such as Member of the 6th and 7th People's Congress of Shenzhen Nanshan District, Committee Member of Nan Shan District Women's Federation, Deputy President of Shenzhen Fashion Creative Industry Association, Deputy President of Shenzhen Property Management Society, Deputy President of Shenzhen Life Science and Biotechnology Association. Ms. Zhang has a degree from Beijing Wuzi University and an EMBA degree from Tsinghua University School of Economics and Management.

Job Titles:

• Chief Financial Officer
• Chief Financial Officer and Vice President of Finance at Shenzhen Hepalink Pharmaceutical Group Co
• Master of Professional Accounting ( MPAcc ), Bachelor of Economics / Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Chief Financial Officer, VP of Finance

Ms. Juan Chen is the Chief Financial Officer and Vice President of Finance at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink") where she participates in the formulation of the Group's long-term strategies and annual business plans and the setting of financial targets for the Group as well as its business units and product lines, in alignment with the company's mid- and long-term strategies. Ms. Chen's scope of work also includes budget development for all of the Group's operations, produce-based cost accounting, internal financial analysis, and financial reporting for Hepalink as required of a listed company. She oversees the building of systems that can enable the integrated management of business activities and finances, as well as track all teams' financial performances against their financial targets. Her team supports the operation of various functions and business segments by deploying financial policies, methodologies, and instruments to monitor financial performance of business units, and help the Group and its business units to meet annual targets by identifying and addressing financial shortcomings. Based on business management needs and financial disclosures that are required of a listed company, Ms. Chen is also responsible for the accounting in the company's finances (accurate accounting of the group's business results and financial disclosures as required of publicly traded companies), ensuring the safety and efficiency of capital allocations, and coordinating the Group's global tax planning. Ms. Chen has over 20 years of experience in financial management at both large multinational enterprises and publicly traded Chinese private companies. Before joining Hepalink, Ms. Chen was the Director of Finance at SF Airline and Head of customer settlement center of SF Express. During her tenure there, Ms. Chen enhanced the company's financial policies, system, and procedures for a receivable clearance operation that reached hundreds of billions of RMB in scale. Furthermore, she effectively reduced risk in capital management, thereafter safeguarded the company's day-to-day operations by deploying a range of digital tools. Meanwhile, Ms. Chen also provided financial advices on major investment decisions by SF Airlines, a subsidiary of SF Express, including the company's acquisition of aircrafts, and executed on the company's financial strategies. During this period, Ms. Chen gained deep insights and experience in digitalized financial management and the management of big data. Prior to that, Ms. Chen served as the Head of business control for IBM Global Technology Service unit of Great China group; as well as the CFO of Finance and Senior Manager of Finance at IBM System technology (Shenzhen) Co., Ltd, and Lenovo System technology (Shenzhen) Co., Ltd., where she gained a global perspective on corporate financial management and accumulated a wealth of experience in the integrated corporate financial management, internal control, and business analysis. Ms. Chen played an integral role in the sale of IBM's personal computer and X86 server businesses and supported the company's transitions with effective financial strategies. Ms. Chen holds a Master of Professional Accounting (MPAcc) degree from Tsinghua University, a Bachelor of Economics degree from Hubei University, and a Chartered Global Management Accountant (CGMA) certificate.

Job Titles:

• Deputy General Manager
• Executive Director
• Executive Director, Deputy

Ms. Tan Li is an Executive Director, Deputy General Manager, and Vice President at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink"), where she as a co-founder, leads corporate strategies, strategic transformation, enterprise resource allocation, facilitating corporate-wide strategic initiatives, and the sales of formulation products in Europe. Since founding in 1998, Hepalink has witnessed tremendous growth under the leadership of its senior executive team in which Ms. Li is a key member, achieving consistent profitability and the due-listing in mainland China and Hong Kong. Hepalink's enoxaparin sodium injections, the company's lead product and the first enoxaparin biosimilar in China and the EU, are being sold to more than 40 countries, winning widespread recognition in markets with high-entry requirements such as the U.S. and the EU. Ms. Li has also made substantial contribution to the strategic transformations of Hepalink, and played a pivotal role in formulating and building the company's tri-engine business model driven by the three core businesses in heparin industrial chain, CDMO services in large molecule biologics, and the acquisition, development and commercialization of innovative drugs. Due to her exceptional leadership at Hepalink, Ms. Li was named a Chinese Woman in Tech by Forbes, a finalist of the 2020 Forbes China Top Businesswomen List, and a recipient of the 2021 Forbes China Best Businesswomen Award. Prior to co-founding Hepalink, Ms. Li was Deputy Chief Engineer and Deputy General Manager of Chongqing Tongda Biological Products Co., Ltd. Ms. Li obtained a Bachelor in Science degree from Sichuan University.

Job Titles:

• Chief Business Officer
• AbbVie U.S in 2013 As Director
• Chief Business Officer / Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• Chief Business Officer of Shenzhen Hepalink Pharmaceutical Group Co

Ms. Tao Han is the Chief Business Officer of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink") where she leads business development, corporate strategies (pipeline, new product planning, clinical development and commercialization strategies), business insights, corporate communications, as well as the development innovative drugs and sales of Hepalink's formulation products in the U.S. (through the company's own commercial organization). Ms. Han has over 20 years of experience in the formulation of clinical development and commercialization strategies. Before joining Hepalink, Ms. Han was Vice President of Corporate Development at CStone Pharmaceuticals; and Vice President and Head of Corporate Development at Ascentage Pharma. While at CStone, Ms. Han made significant contribution to the trial design of a lead asset for the treatment of first-line esophageal squamous cell carcinoma by building effective business insights capabilities for the company, shortening the asset's journey-to-NDA submission by seven quarters. During her time at Ascentage, Ms. Han played an integral role in the company's successful IPO in Hong Kong. Prior to that, Ms. Han joined AbbVie U.S in 2013 as Director, Business Insights and Strategies of the blood cancer franchise where she oversaw global product lifecycle management and commercialization strategies for Venclexta™ and Imbruvica™, two of the company's lead oncology assets. Her work in Business Insights played an essential role for the indication expansion of Venclexta™, and the formulation of the clinical development strategy for Venclexta™ in the treatment of acute myeloid leukemia. For this achievement, she was awarded the 2015 AbbVie Global President Award. From 2009 to 2013, Ms. Han was Director at Kantar Health in China where she led the drug development and commercialization strategy consulting to dozens of multinational pharmaceutical companies. Ms. Han has an MBA degree from the University of Connecticut, United States.

Job Titles:

• Master of Medicine
• Regional General Manager of Sales and Marketing for Europe at Shenzhen Hepalink Pharmaceutical Group Co

Ms. Wen Shi is currently the Regional General Manager of Sales and Marketing for Europe at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or "Hepalink") where she leads the sales and marketing of Hepalink's enoxaparin formulation products, business development, distributorship management as well as the company's subsidiaries in overseas markets. Ms. Shi has over 25 years of rich operational and managerial experience in the lifecycle management and business development of pharmaceutical and vaccine products. Before joining Hepalink, Ms. Shi was Commercial Director at UK's Mundi Pharma, where she oversaw the in-licensing of new products. Prior to that, during her time at Pfizer from 2011 to 2016, Ms. Shi served in a core leadership role for the launch of Prevenar 13 in adult indications at Pfizer's European HQ. She led the successful launches of the product for two indications in the European market and received the Pfizer Global Award for her achievements. Previously, Ms. Shi served in various global management positions at Sanofi Pasture and GSK having accumulated years of experience in the sales and marketing and business development for vaccine products. Ms. Shi has a Master of Clinical Medicine degree from Shanghai Jiao Tong University School of Medicine, and an MBA from Reims Management School of France.

Job Titles:

• Chairman of Hepalink 's Scientific Advisory Board

Doctor of Cancer Research at Machon Weizmann Lemada, Israel Completed his postdoctoral training at UCLA and UCSF Served as a visiting professor at Harvard University and the Memorial Sloan-Kettering Cancer Center, as well as the National University of Australia. Currently professor at Technion Integrated Cancer Center, Israel Prof. Israel Vlodavsky is one of the first few scientists who recognized the active role of extracellular matrix (ECM) in coordinating cellular responses to normal and pathological conditions. His discovery about ECM being a reservoir of biologically active molecules has established the foundation enabling the current search in tumor microenvironment and its role in cancer progressions. Another one of Prof. Vlodavsky's most celebrated achievements is the cloning and encoding of heparanase which plays a key role in tissue remodeling, caner metastasis, angiogenesis, inflammations, diabetes, and renal dysfunctions. Prof. Vlodavsky is a pioneer that offered groundbreaking knowledge about and new therapies for the treatment of cancer and a range of other diseases.

Job Titles:

• Secretary to Hepalink 's Scientific Advisory Board

Chinese scientist with Swedish nationality, and holds a PhD degree in biochemistry Currently professor at the Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden; serves as a PhD supervisor, and Research Projects Leader

Job Titles:

• Member of Hepalink 's Scientific Advisory Board / Doctor of Immunology at Machon Weizmann Lemada, Israel

Doctor of Immunology at Machon Weizmann Lemada, Israel Post-doctor at Immunology and Neuroimmunology at Stanford University Formerly Visiting Professor at the Department of Neurology of School of Medicine, Stanford University Currently Professor in the Department of Immunology at the Ruth and Bruce Rappaport Faculty of Medicine Prof. Nathan Karin has worked on areas such as cancer immunology, regulation of inflammatory processes within the central nervous system, and potential mechanisms for leukocyte migration and function. His research on adhesion molecules and cell migration significantly contributed to the development of lead therapies for the treatment of multiple sclerosis, and his discovery of chemokines had led to the current understanding about chemokines and cytokines and their role in inflammatory autoimmune disease and cancer immunology.